background
effect
corticosteroid
treatment
viral
load
sever
acut
respiratori
syndrom
sar
patient
unknown
object
compar
plasma
sarscov
rna
concentr
ribavirintr
patient
receiv
earli
hydrocortison
therapi
receiv
placebo
studi
design
serial
plasma
sarscov
rna
concentr
measur
set
prospect
random
doubleblind
placebocontrol
trial
design
assess
efficaci
earli
day
ill
hydrocortison
use
previous
healthi
sar
patient
analyz
sarscov
rna
quantifi
use
onestep
realtim
rtpcr
assay
target
nucleocapsid
gene
result
among
nonicu
case
sarscov
rna
detect
plasma
sinc
day
fever
onset
viral
concentr
peak
first
week
rapidli
declin
second
week
ill
day
cumul
proport
patient
undetect
viru
plasma
respect
plasma
sarscov
rna
concentr
second
third
week
ill
significantli
higher
patient
receiv
initi
hydrocortison
treatment
n
compar
receiv
placebo
n
auc
mannwhitney
p
median
time
sarscov
becom
undetect
plasma
day
day
versu
day
day
respect
conclus
find
suggest
earli
corticosteroid
treatment
associ
higher
subsequ
plasma
viral
load
sever
acut
respiratori
syndrom
sar
newli
emerg
infecti
diseas
littl
known
pathogenesi
optim
treatment
regimen
peiri
et
al
use
corticosteroid
therapi
reduc
possibl
immunemedi
pulmonari
damag
remain
controversi
oba
previous
describ
realtim
quantit
revers
transcriptas
polymeras
chain
reaction
rtpcr
plasmaserum
assay
earli
diagnosi
sar
ng
et
al
studi
analyz
serial
plasma
sarscov
rna
concentr
measur
set
random
placebocontrol
trial
initi
design
assess
efficaci
earli
hydrocortison
use
initi
day
fever
onset
previous
healthi
sar
patient
effect
corticosteroid
treatment
plasma
viral
load
studi
compar
hydrocortisonetr
patient
versu
receiv
placebo
prospect
random
doubleblind
placebocontrol
trial
assess
clinic
efficaci
earli
corticosteroid
use
sar
patient
conduct
april
may
two
region
hospit
hong
kong
ethic
approv
obtain
instituion
review
board
chines
univers
hong
kong
howev
studi
termin
hong
kong
outbreak
end
june
studi
inclus
criteria
probabl
case
sar
without
laboratori
confirm
accord
center
diseas
control
prevent
cdc
case
definit
cdc
age
year
exclus
criteria
late
present
day
symptom
onset
presenc
comorbid
eg
renal
impair
liver
failur
congest
heart
failur
major
cardiovascular
diseas
chronic
lung
diseas
malign
etc
evid
respiratori
failur
admiss
defin
blood
oxygen
satur
sa
oxygen
tension
pa
kpa
without
supplement
oxygen
therapi
ie
room
air
inform
consent
patient
obtain
routin
serial
laboratori
investig
plain
chest
radiograph
perform
describ
sung
et
al
extent
pulmonari
infiltr
frontal
chest
radiograph
score
percentag
radiologist
wong
et
al
convent
qualit
sarscov
rtpcr
assay
perform
weekli
throat
gargl
stool
specimen
patient
pair
sarscov
serolog
indirect
immunofluoresc
assay
week
apart
also
obatin
chan
et
al
plasma
sarscov
rna
concentr
measur
daili
day
admiss
discharg
plasma
sarscov
rna
quantit
blood
sampl
collect
edtacontain
tube
plasma
obtain
centrifug
blood
sampl
g
min
follow
g
min
viral
rna
extract
ml
plasma
qiaamp
viral
rna
mini
kit
qiagen
hilden
germani
accord
manufactur
recommend
rna
elut
l
ave
buffer
includ
kit
store
c
one
step
quantit
realtim
rtpcr
target
nucleocapsid
gene
sarscov
perform
previous
describ
determin
plasma
viral
rna
concentr
ng
et
al
sampl
analyz
duplic
calibr
curv
run
parallel
analysi
multipl
neg
water
blank
also
includ
everi
analysi
clinic
treatment
protocol
consist
initi
antibacteri
therapi
communityacquir
pneumonia
sung
et
al
upon
admiss
intraven
ribavirin
therapi
dose
mg
eight
hourli
given
clinic
respons
h
total
day
also
case
randomis
doubleblind
fashion
receiv
either
earli
intraven
hydrocortison
mg
everi
eight
hourli
intraven
normal
salin
ml
eight
hourli
placebo
total
day
puls
methylprednisolon
given
rescu
therapi
puls
intraven
highdos
methylprednisolon
mgday
three
consecut
day
given
case
persistentrecurr
fever
plu
radiograph
progress
lung
opac
hypoxemia
rescu
therapi
puls
methylprednisolon
given
requir
clinic
radiolog
improv
archiv
total
g
sung
et
al
detail
clinic
radiolog
laboratori
data
patient
treat
similarli
describ
elsewher
sung
et
al
hui
et
al
press
data
analyz
use
summari
statist
area
curv
auc
method
mannwhitney
test
use
compar
plasma
viral
concentr
differ
arm
across
time
quantifi
mean
auc
calcul
linear
trapezoid
method
spearman
rank
correl
coeffici
use
assess
correl
plasma
viral
concentr
extent
lung
opac
plain
chest
radiograph
nadir
lymphocyt
count
spss
window
releas
spss
inc
chicago
il
usa
use
analys
level
signific
set
comparison
total
patient
recruit
median
age
year
rang
year
male
femal
ratio
previous
healthi
individu
pair
serolog
test
confirm
sarscov
infect
case
igg
titer
five
bilater
lung
infiltr
one
case
requir
supplement
oxygen
therapi
recov
discharg
unev
without
requir
icu
care
remain
patient
transfer
icu
mechan
ventil
respiratori
failur
die
convalesc
serum
could
obtain
diagnosi
sar
confirm
two
throat
wash
test
posit
sarscov
rtpcr
clinic
radiolog
laboratori
data
cohort
summar
tabl
total
nine
patient
nonicu
group
receiv
earli
hydrocortison
treatment
initi
mean
interv
day
ci
fever
onset
normal
salin
given
remain
seven
case
highdos
methylprednisolon
given
six
patient
placebo
group
mean
cumul
dose
g
four
patient
hydrocortison
group
mean
cumul
dose
g
respect
initi
mean
interv
day
ill
onset
singl
icu
case
receiv
earli
hydrocortison
treatment
subsequ
highdos
methylprednisolon
therapi
detect
percentag
patient
plasma
sarscov
rna
nonicu
patient
hydrocortisonetr
group
versu
placebo
group
across
time
depict
fig
sarscov
rna
detect
plasma
sinc
day
ill
onset
overal
mean
time
sarscov
rna
becom
undetect
plasma
day
ci
fever
onset
cumul
proport
patient
undetect
viru
day
respect
median
time
sarscov
rna
becom
undetect
plasma
day
rang
day
versu
day
rang
day
hydrocortison
placebo
group
respect
mannwhitney
p
profil
mean
plasma
sarscov
rna
concentr
nonicu
case
hydrocortisonetr
group
versu
placebo
group
depict
fig
gener
peak
plasma
viral
load
reach
within
first
week
ill
rapidli
declin
second
week
mean
peak
plasma
sarscov
rna
concentr
copiesml
ci
copiesml
peak
valu
singl
icu
case
copiesml
plasma
viral
load
measur
two
treatment
arm
compar
plasma
week
ill
statist
significantli
higher
patient
receiv
earli
hydrocortison
treatment
n
compar
receiv
placebo
n
auc
mannwhitney
p
differ
plasma
viral
rna
concentr
detect
ever
receiv
subsequ
high
dose
methylprednisolon
n
n
auc
mannwhitney
p
addit
patient
upper
respiratori
specimen
test
posit
sarscov
rtpcr
n
statist
significantli
higher
plasma
viral
rna
concentr
compar
case
test
neg
n
auc
mannwhitney
test
p
differ
plasma
viral
rna
concentr
detect
fecal
specimen
posit
n
neg
n
patient
auc
mannwhitney
test
p
furthermor
statist
signific
differ
plasma
viral
rna
concentr
detect
patient
ever
bilater
lung
infiltr
n
n
auc
mannwhitney
p
signific
correl
found
plasma
sarscov
rna
concentr
extent
lung
opac
plain
chest
radiograph
spearman
r
respect
peak
valu
spearman
r
also
signific
correl
peak
plasma
sarscov
rna
concentr
nadir
lymphocyt
count
spearman
r
found
young
previous
healthi
adult
sar
patient
sarscov
rna
detect
plasma
sinc
day
fever
onset
reach
peak
concentr
first
week
declin
rapidli
second
week
ill
earli
hydrocortison
treatment
initi
day
ill
associ
significantli
higher
subsequ
plasma
viral
concentr
second
third
week
durat
viraemia
may
also
prolong
find
confirm
previou
observ
viral
load
sar
patient
declin
rapidli
second
week
ill
initi
peak
day
upper
respiratori
secret
peiri
et
al
ng
et
al
sinc
ribavirin
demonstr
antivir
activ
sarscov
cyranoski
host
immun
defens
like
respons
viral
clearanc
shown
studi
earli
initi
corticosteroid
treatment
viral
replic
phase
peiri
et
al
wong
hui
first
week
ill
result
delay
viral
clearanc
thu
higher
subsequ
plasma
viral
load
possibl
relat
immunosuppress
effect
durat
viraemia
might
also
prolong
median
time
undetect
day
versu
day
though
differ
reach
statist
signific
use
corticosteroid
therapi
sar
patient
controversi
oba
immunosuppress
effect
sar
viral
induc
pneumonia
potenti
side
effect
eg
superimpos
bacterialfung
infect
hyperglycemia
electrolyt
imbal
psychosi
lack
evid
clinic
efficaci
randomizedplacebocontrol
studi
main
concern
wang
et
al
peiri
et
al
corticosteroid
given
reduc
possibl
immunopatholog
damag
preliminari
data
retrospect
nonrandom
studi
demonstr
clinic
benefit
sar
patient
receiv
corticosteroid
treatment
sung
et
al
ho
et
al
howev
optim
time
dosag
therapi
uncertain
result
analysi
support
use
corticosteroid
therapi
earli
ill
delay
viral
clearanc
especi
concomit
effect
antivir
therapi
given
fact
shown
separ
studi
earli
lowdos
corticosteroidhydrocortison
therapi
fail
halt
diseas
progress
case
sung
et
al
although
observ
abrupt
rebound
viraemia
cohort
puls
methylprednisolon
therapi
given
first
week
studi
need
clarifi
issu
meanwhil
call
cautiou
use
therapi
use
prefer
given
later
cours
diseas
overexuber
host
immun
respons
caus
patholog
lung
damag
eg
second
week
follow
clinic
deterior
peiri
et
al
loutfi
et
al
wong
hui
sarscov
viral
load
declin
significantli
addit
earlier
detect
sarscov
plasma
viral
rna
quantit
provid
valuabl
prognost
inform
ng
et
al
studi
verifi
significantli
higher
plasma
viral
load
present
patient
ever
sarscov
detect
upper
respiratori
specimen
qualit
rtpcr
method
like
result
higher
concomit
viral
load
upper
respiratori
secret
fact
posit
qualit
rtpcr
assay
high
viral
load
upper
respiratori
secret
high
plasma
viral
load
admiss
predict
advers
clinic
outcom
tsang
et
al
cheng
et
al
ng
et
al
lack
signific
correl
plasma
viral
load
fecal
specimen
rtpcr
posit
radiograph
extent
lung
infiltr
degre
lymphopenia
may
actual
reflect
complex
pathogen
mechan
sar
eg
immunemedi
pulmonari
tissu
damag
lymphocyt
apoptosi
versu
direct
viral
lytic
action
requir
studi
cheng
et
al
peiri
et
al
wong
hui
odonnel
et
al
studi
limit
small
sampl
size
patient
advanc
age
comorbid
immunocompromis
exclud
moreov
viral
load
profil
among
sever
sar
case
clinic
consequ
higher
plasma
viral
load
earli
hydrocortison
treat
patient
would
need
investig
studi
demonstr
earli
corticosteroid
treatment
associ
higher
subsequ
plasma
viral
load
therefor
avoid
judici
use
corticosteroid
therapi
sar
advis
